Feasibility of Real‐Time Central Surgical Review for Patients with Advanced‐Stage Hepatoblastoma in the JPLT3 Trial

Tomoro Hishiki, Shohei Honda, Yuichi Takama, Yukihiro Inomata, Hideaki Okajima, Ken Hoshino, Tatsuya Suzuki, Ryota Souzaki, Motoshi Wada, Mureo Kasahara, Koichi Mizuta, Takaharu Oue, Akiko Yokoi, Takuro Kazama, Shugo Komatsu, Isamu Saeki, Osamu Miyazaki, Tetsuya Takimoto, Kohmei Ida, Kenichiro WatanabeEiso Hiyama

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

In the JPLT3 study, a real‐time central surgical reviewing (CSR) system was employed aimed at facilitating early referral of candidates for liver transplantation (LTx) to centers with pediatric LTx services. The expected consequence was surgery, including LTx, conducted at the appro-priate time in all cases. This study aimed to review the effect of CSR on institutional surgical deci-sions in cases enrolled in the JPLT3 study. Real‐time CSR was performed in cases in which complex surgeries were expected, using images obtained after two courses of preoperative chemotherapy. Using the cloud‐based remote image viewing system, an expert panel consisting of pediatric and transplant surgeons reviewed the images and commented on the expected surgical strategy or the necessity of transferring the patient to a transplant unit. The results were summarized and reported to the treating institutions. A total of 41 reviews were conducted for 35 patients, and 16 cases were evaluated as possible candidates for LTx, with the treating institutions being advised to consult a transplant center. Most of the reviewed cases promptly underwent definitive liver surgeries, including LTx per protocol.

Original languageEnglish
Article number234
JournalChildren
Volume9
Issue number2
DOIs
Publication statusPublished - 02-2022

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'Feasibility of Real‐Time Central Surgical Review for Patients with Advanced‐Stage Hepatoblastoma in the JPLT3 Trial'. Together they form a unique fingerprint.

Cite this